ArticleScientific reports2026
Explainable machine learning-driven identification of heart failure biomarkers: a multi-model feature selection approach with SHAP-based interpretability.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Heart failure (HF) remains a major clinical challenge due to its complex pathophysiology and the limitations of existing biomarkers. In this study, we developed a robust machine learning (ML) framework to identify novel transcriptomic signatures of HF. Three GEO RNA-seq datasets (GSE141910, GSE198945, GSE263297) were integrated and harmonized, followed by a "split-first" strategy for training (70%) and testing (30%). We employed a triphasic feature selection process-integrating LASSO, Random Forest (RF), and SVM-RFE-to identify candidate genes. A 10-model ensemble system was evaluated using Leave-One-Study-Out Cross-Validation (LOSO-CV) and interpreted via SHAP values. Findings were validated using an independent external cohort (GSE135055) and experimental RT-qPCR in a local clinical cohort. Three potential biomarkers-FNDC1, LPCAT3, and TIMP2-were prioritized. FNDC1 and TIMP2 were significantly upregulated, while LPCAT3 was suppressed in HF tissues (p < 0.001), patterns consistently confirmed by qPCR. The ML models demonstrated high diagnostic stability, with peak LOSO-CV AUCs reaching 0.973 and maintaining robustness in external validation (AUC up to 0.876). SHAP analysis identified FNDC1 as the most influential predictor. Functional enrichment linked these signatures to extracellular matrix remodeling and lipid metabolism. These findings suggest that FNDC1, LPCAT3, and TIMP2 may serve as potential biomarkers associated with the pathological mechanisms of HF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.